There are currently 433 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
Recruiting
This is a phase I study looking at the safety of cancer peptides combined with adjuvant and GM-CSF in subjects with estrogen receptor (ESR) positive breast cancer. The primary objective of the study is to determine the safety of of the peptide vaccine. The secondary objective is to evaluate the immune response to the vaccine. The peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. A pep... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Breast Cancer
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Recruiting
This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Recruiting
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
HIIT Following Breast Cancer Chemotherapy
Recruiting
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training... Read More
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
10/22/2024
Locations: Integrative Cardiovascular Physiology Laboratory, University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Prospective Breast Cancer Biospecimen Collection
Recruiting
Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date of recurrence, metastases, and/or death
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
Recruiting
This is a single-arm, open-label study testing the effects of neoadjuvant therapy with the aromatase inhibitor letrozole in post-menopausal women with Stage I-III ER+, HER2- breast cancer. Eligible subjects will be treated with letrozole therapy for 4 to 24 weeks prior to surgical resection of the tumor. Tumor specimens obtained at baseline (diagnostic biopsy) and at surgery (surgical specimen) will be compared using molecular analyses. A subset of subjects will be asked to provide an optional r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire +1 locations
Conditions: Breast Cancer, ER Positive Breast Cancer
Biennial CEM in Women with a Personal History of Breast Cancer
Recruiting
This is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast cancer.
Gender:
FEMALE
Ages:
Between 30 years and 79 years
Trial Updated:
10/16/2024
Locations: UPMC Magee-Womens Imaging - Bethel Park, Bethel Park, Pennsylvania +4 locations
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancer Female, Neoplasms
Evaluation of the Bexa Breast Examination
Recruiting
Objective: The "Bexa Breast Exam," or "BBE," for the purposes of this study is defined as the use of a Bexa device in conjunction with a portable, focused ultrasound examination to identify and further evaluate abnormal breast masses including cancer. Commercially, this combination of Bexa plus focused ultrasound is called "Bexa Breast ExamTM," and abbreviated as, "BBE." This study compares the Bexa Breast Exam (BBE) to the standard of care (digital breast tomosynthesis) in detecting masses and... Read More
Gender:
FEMALE
Ages:
Between 30 years and 75 years
Trial Updated:
10/16/2024
Locations: Hendrick Health - Vera West Women's Center, Abilene, Texas
Conditions: Breast Cancer
UNC Pleural Fluid Registry
Recruiting
Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid regi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: UNC Lingeberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion, Empyema
Perioperative Mindfulness Proposal
Recruiting
The purpose of this study is to determine if a regular meditation and breath work practice started before surgery and continued through post-surgical recovery can improve anxiety and pain related to breast cancer and its treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Breast Cancer, DCIS
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Providence St. Johns Health Center, Santa Monica, California +6 locations
Conditions: Breast Cancer
Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling
Recruiting
The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Rochester, Rochester, New York
Conditions: Breast Cancer